Chemical Compound

L-Phenylalaninamide, (aS)-a-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-; L-Phenylalaninamide, (aS)-a-[(4-morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]- (9CI); (aS)-a-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide; Carfilzomib; Kyprolis; PR 171

CAS Registry Number 868540-17-4
返回搜索 申请报价
L-Phenylalaninamide, (aS)-a-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-; L-Phenylalaninamide, (aS)-a-[(4-morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]- (9CI); (aS)-a-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide; Carfilzomib; Kyprolis; PR 171 结构式
Primary record

L-Phenylalaninamide, (aS)-a-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-; L-Phenylalaninamide, (aS)-a-[(4-morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]- (9CI); (aS)-a-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide; Carfilzomib; Kyprolis; PR 171

库存
6,203 克
纯度
99.1 %
CAS
868540-17-4

化合物标识与属性

CAS
868540-17-4
PubChem CID
11556711
SMILES
CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4
Canonical SMILES
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1

名称与同义词

  • Carfilzomib
  • Kyprolis
  • 868540-17-4
  • Carfilzomib (PR-171)
  • carfilzomibum
  • PR-171
  • Carfilzomib [USAN]
  • Kyprolis (TN)
  • Carfilzomib (PR171)
  • Carfilzomib(PR171)
  • Carfilzomib; PR171
  • Carfilzomib (Standard)
  • UNII-72X6E3J5AR
  • Carfilzomib [USAN:INN]
  • RefChem:57059
  • CARFILZOMIB [MI]
  • 72X6E3J5AR
  • CARFILZOMIB [INN]
  • CARFILZOMIB [JAN]
  • DTXSID4048690
  • D00UVA
  • CARFILZOMIB [VANDF]
  • Carfilzomib (PR-171)?
  • CHEMBL451887
  • C40H57N5O7
  • MFCD11040997
  • SCHEMBL85165
  • CARFILZOMIB [WHO-DD]
  • DTXCID0028616
  • cc-684
  • CHEBI:65347
  • MLS006011102
  • NSC-758252
  • Carfilzomib (JAN/USAN/INN)
  • GTPL7420
  • orb1307429
  • PR171
  • QCR-96
  • Carfilzomib?PR-171?/Kyprolis
  • AMY4357
  • CARFILZOMIB [ORANGE BOOK]
  • L01XX45
  • BLMPQMFVWMYDKT-NZTKNTHTSA-N
  • GLXC-90068
  • AOB87759
  • EX-A2037
  • KS-00000SR1
  • ONO-7057
  • Tox21_113079
  • AN-217
  • BDBM50277889
  • EBC-17178
  • HY-10455R
  • NCGC00249613-01
  • NSC756640
  • NSC758252
  • PR 171
  • s2853
  • ZINC49841054
  • AKOS025401910
  • Tox21_113079_1
  • ACN-039824
  • CCG-270405
  • CS-0984
  • CS-W004540
  • DB08889
  • FC46443
  • NSC 758252
  • NSC-756640
  • RL05381
  • CID11556711
  • NCGC00249613-02
  • NCGC00249613-03
  • NCGC00249613-08
  • NCGC00249613-11
  • NCGC00249613-13
  • AC-27051
  • AK546882
  • AS-17059
  • BC251806
  • BP-43632
  • CID 11556711
  • CID:11556711
  • HY-10455
  • SC-91032
  • SMR004660024
  • SY068813
  • SID:124360326
  • AB0008111
  • CAS-868540-17-4
  • NS00072616
  • PX-171-007
  • SW218090-2
  • Y0441
  • J2.711.864J
  • A11278
  • D08880
  • S-7798
  • AB01565867_02
  • A904242
  • C524865
  • F951459
  • SR-01000941582
  • (alphaS)-alpha-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide
  • SR-01000941582-1
  • BRD-K15179879-001-03-2
  • Q15366934
  • (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
  • N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide
  • B0084-305419
  • (2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
  • (2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide
  • (S)-4-methyl-N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide
  • Carfilzomib, 99%, irreversible proteasome inhibitor - 100MG 100mg
  • (2S)-N-[(1S)-1-benzyl-2-[[(1S)-3-methyl-1-[(2R)-2-methyloxirane-2-carbonyl]butyl]amino]-2-oxo-ethyl]-4-methyl-2-[[(2S)-2-[(2-morpholinoacetyl)amino]-4-phenyl-butanoyl]amino]pentanamide
  • (S)-4-Methyl-N-((S)-1-((S)-4-Methyl-1-((R)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylaMino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-MorpholinoacetaMido)-4-phenylbutanaMido)pentanaMide
  • L-Phenylalaninamide, (alphaS)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-L-leucyl-N-((1S)-3-methyl-1-(((2R)-2-methyloxiranyl)carbonyl)butyl)-
  • (|AS)-|A-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide
  • (2R)-2-Methyl-2-[N-[(2S)-2-[(morpholinoacetyl)amino]-4-phenylbutyryl]-L-Leu-L-Phe-L-Leu-]oxirane
  • (2S)-4-methyl-N-[(1S)-1-{[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]carbamoyl}-2-phenylethyl]-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]-4-phenylbutanamido]pentanamide
  • (2S)-N-[(1S)-1-Benzyl-2-[[(1S)-3-methyl-1-[[(2R)-2-methyloxiran-2-yl]carbonyl]butyl]amino]-2-oxoethyl]-4-methyl-2-[[(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
  • (alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phenylalaninamide
  • (aS)-a-[(4-Morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-phenylalani namide
  • (S)-4-Methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbu
  • (S)-4-Methyl-N-[(S)-1-[[(S)-4-methyl-1-[(R)-2-methyloxiran-2-yl]-1-oxo-2-pentyl]amino]-1-oxo-3-phenyl-2-propyl]-2-[(S)-2-(2-morpholinoacetamido)-4-phenylbutanamido]pentanamide
  • L-PHENYLALANINAMIDE, (.ALPHA.S)-.ALPHA.-((4-MORPHOLINYLACETYL)AMINO)BENZENEBUTANOYL-L-LEUCYL-N-((1S)-3-METHYL-1-(((2R)-2-METHYLOXIRANYL)CARBONYL)BUTYL)-
  • L-Phenylalaninamide, (aS)-a-[[2-(4-morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-; L-Phenylalaninamide, (aS)-a-[(4-morpholinylacetyl)amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]- (9CI); (aS)-a-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide; Carfilzomib; Kyprolis; PR 171
  • N-((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)-L-leucyl-N-((2S)-4-methyl-1-((2R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)-L-phenylalaninamide
  • N-(Morpholinoacetyl)-4-phenyl-L-Abu-L-Leu-L-Phe-[(S)-3-methyl-1-[[(R)-2-methyloxiranyl]carbonyl]butyl]NH2
  • N-{(2S)-2-[2-(Morpholin-4-yl)acetamido]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide